Manufactured Object
AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results
Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide
Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends
Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment
Agentic AI is Here: Real-World Applications in Life Sciences & Healthcare (2025 Update)
Agentic AI; life sciences; healthcare; R&D; pharma; personalized medicine; pharmacovigilance; commercialization; automation; data analysis
FDA Launches PreCheck Program to Accelerate Domestic Drug Manufacturing
FDA PreCheck; domestic drug manufacturing; pharmaceutical supply chain; API; regulatory streamlining; facility construction; national security; Trump administration
Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial
Praxis Precision Medicines; vormatrigine; epilepsy; seizures; RADIANT study; focal onset seizures; Phase 2 trial; sodium channel blocker
Praxis touts ‘best-in-disease’ epilepsy data, but shares dip
Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market
Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise
royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment
Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street
Alnylam Pharmaceuticals; market cap; Amvuttra; heart disease; ATTR-CM; stock surge; Q2 2025 earnings; revenue growth
Frazier Life Sciences Raises $1.3 Billion Amid Biotech Downturn
Frazier Life Sciences; venture capital; biotech; $1.3 billion raise; early-stage investments; biopharmaceutical startups; oversubscribed fund; therapeutics
Merck & Co. Targets $3B in Cost Savings Through Restructuring, Including Job Cuts
Merck & Co.; cost-cutting; $3 billion savings; restructuring; job cuts; 2027 target; restructuring charges; R&D; manufacturing investments